X4 Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics targeting diseases resulting from dysfunction of the CXCR4 pathway, particularly rare immune disorders with limited treatment options; its lead product, mavorixafor (marketed as XOLREMDI in the U.S.), is an oral, once-daily small-molecule CXCR4 antagonist approved for the treatment of adult patients with WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), a rare primary immunodeficiency, and is under investigation in the ongoing global Phase 3 4WARD trial for chronic neutropenia, including severe congenital neutropenia, idiopathic neutropenia, and neutropenia associated with certain genetic syndromes. Founded in 2014 and headquartered in Boston, Massachusetts, the company operates primarily in the U.S. with ex-U.S. partnerships for mavorixafor commercialization and serves patients with rare diseases of the immune system through its expertise in CXCR4 biology. Recent developments include a $60 million private placement equity financing in August 2025 led by Coastlands Capital with participation from Bain Capital Life Sciences, New Enterprise Associates, and others to support the 4WARD trial and XOLREMDI commercialization, accompanied by management and board changes featuring Dr. Adam Craig as Executive Chairman; a $135 million underwritten public offering priced in late October 2025, which closed at approximately $155 million; strategic restructuring in February 2025 and September 2025 to optimize costs by $30-35 million annually, sharpen focus on chronic neutropenia, and enhance U.S. promotion of XOLREMDI; FDA Fast Track Designation for mavorixafor in chronic neutropenia-related indications; and EMA validation of a Marketing Authorization Application for mavorixafor licensed to Norgine for development outside the U.S.
Company News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $11.25 Consensus Price Target from Brokerages
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)